ArticleFrontiers in cellular and infection microbiology2026
Early-life gammaherpesvirus infection results in an expanded long-term latent reservoir.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Gammaherpesviruses are ubiquitous oncogenic pathogens that establish lifelong latency, are associated with multiple types of malignancies, and are increasingly believed to play a role in autoimmune disease. Human Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV) frequently infect across various stages of childhood development. Nevertheless, how infection during the earliest stages of life, when immune defenses are still developing, shapes the risk of malignant disease and autoimmunity remains poorly understood. Here, we characterized acute and chronic infection following early-life inoculation with murine gammaherpesvirus 68 (MHV68). We infected mice at postnatal day P3, P5, or P8, ages that, in the compressed developmental timeline of the mouse model, correspond to the progressive immune maturation that occurs in human neonatal to infancy stages. Mice infected during early life displayed age- and dose-dependent susceptibility to MHV68 infection, with the approximate lethal dose 50% (LD50) values ranging from 200 plaque forming units (PFU) in mice inoculated at P3 to 10,000 PFU in mice inoculated at P8. Severe disease was accompanied by substantial weight loss prior to death. Following intranasal inoculation of P8 pups, MHV68 replicated rapidly in the lung, reaching high titers by 3 days, achieving higher lung titers than adult mice at 5 days. Nevertheless, acute replication was largely resolved by 16 days in surviving animals. Early-life infection induced splenomegaly and resulted in the establishment of latency at frequencies similar to those of adult mice. In contrast, mice infected as neonates maintained 14-fold higher frequencies of latently infected cells than adults during the long-term stable phase of latency, months after clearance of a lytic infection, suggesting that early-life infection substantially alters the long-term latent reservoir. Together, these data demonstrate for the first time that gammaherpesvirus exposure during early life imprints a long-lasting increase in latency burden and establishes a foundation to determine potential implications for malignancy and autoimmune risk later in life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.